When hydrocortisone was made available for clinical trials in the spring of 1951, three facts seemed relevant:

1. The hormone was the principal, probably the natural, glycogenic steroid secreted by the adrenal cortex (Hechter, 1950; Hechter and others, 1951; Reich and others, 1950; Savard and others, 1952; Bush, 1951; Conn and others, 1951; Jacobsen and Pincus, 1951; Pincus, 1949; Mason, 1950).

2. It was considerably more potent than cortisone in certain metabolic activities, as measured by laboratory experiments in animals (Ingle and Kuizenga, 1945; Pabst and others, 1947).

3. It possessed antirheumatic activity, this having been demonstrated by Hench, Kendall, Slocumb, and Polley (1950) in a rheumatoid arthritic patient given 900 mg. of the substance over a 12-day period.

During 1951 and 1952 clinical studies were conducted to compare the therapeutic effectiveness of hydrocortisone and cortisone in patients with rheumatoid arthritis (Boland, 1952a, b, c, d; 1953a, b; 1954; Boland and Headley, 1952).

The general results of these studies may be summarized as follows:

1. The pattern of improvement resulting from the administration of the two steroids was much the same, but smaller initial suppressive doses of hydrocortisone were required to produce corresponding inhibition of the disease manifestations.

2. By comparing the effects of oral doses in the same patient, the antirheumatic potency of hydrocortisone was estimated to be about 50 per cent. greater than that of cortisone acetate or its free ester. In other words, the average milligram dosage of hydrocortisone needed for roughly the same degree of improvement was approximately two-thirds that of cortisone.

3. Smaller maintenance doses of hydrocortisone were found to provide equal or superior rheumatic control, and when these were used, certain endocrine complications appeared to be fewer or less pronounced, especially psychic stimulation, salt-and-water retention, and excessive appetite.

These preliminary observations suggested that there might be a greater dissociation between the desirable anti-inflammatory action and certain undesirable physiological effects with hydrocortisone than with cortisone, and that hydrocortisone might possess a higher therapeutic index—i.e. it might provide equal or greater benefits with smaller doses and fewer or less marked untoward reactions.

Subsequently a study of the effects of oral hydrocortisone given uninterruptedly was undertaken in a large series of patients with rheumatoid arthritis, the relatively short-term results of which have been published (Boland, 1953b; 1954). It now seems opportune, particularly since new synthetic analogues of the adrenocortical hormones have been discovered, to record the results of longer-term observations.

**Present Analysis**

For this report the results of prolonged oral hydrocortisone therapy* in 150 consecutive patients with active peripheral rheumatoid arthritis were analysed. As statistical results are necessarily contingent on a number of factors (including the composition of the series in relation to disease severity and duration, therapeutic plan and objective, method of dosage regulation, opinion as to what constitutes satisfactory response, and judgment as to the acceptability and safety of hormonal complications), some of these aspects, as applied to the present study, deserve clarification.

Each patient selected for the study first had been given a fair but unsuccessful trial on conventional conservative measures. The majority of the patients suffered from more severe forms of the disease; the arthritis was graded as severe in 39 patients (26 per cent.), moderately severe in seventy (47 per

* The hydrocortisone (free alcohol) used for this investigation was supplied in part through the courtesy of the Medical Department, Merck and Co., Inc., Rahway, N.J.
ORAL HYDROCORTISONE IN RHEUMATOID ARTHRITIS

cent.), and moderate in 41 (27 per cent.). No patients with mild disease were included.

The guiding therapeutic policy was to maintain as much relief as possible with doses of hydrocortisone which could be well tolerated. Complete inhibition of the disease manifestations and total functional rehabilitation were not sought unless these could be accomplished with so-called safe levels of dosage. Submaximal improvement of about 75 to 85 per cent. of the pretreatment status was considered optimal for long-term administration. This policy was adopted because it was recognized that benefits from the hormone were only suppressive, not curative, and it had been learned from previous experience with cortisone that the incidence and severity of hormonal complications were directly related to the size of dose employed, and that their occurrence was a major factor influencing the success of long-term therapy.

Adequate or major improvement by our appraisals meant very marked or marked, and corresponded to overall improvement of approximately 75 per cent. or more as compared with the pretreatment status. It should be emphasized that improvement designated as inadequate was at least worthwhile or treatment would have been discontinued.

The following plan of dosage, consisting of three stages, was used:

(a) Initial Suppressive Doses.—As a rule, total daily dosages in the neighbourhood of the following were employed at the beginning: for severe cases, 50 to 70 mg.; for moderately severe cases, 40 to 60 mg.; for moderate cases, 40 to 50 mg. These amounts were continued until the clinical manifestations were satisfactorily suppressed, ordinarily for one to three weeks.

(b) Reduction of Dosage.—Dosage was then gradually lowered in stepdown fashion, reductions of 5 mg. being made every 7 to 14 days, or sometimes even more slowly. The smallest total daily amount which would control the manifestations adequately, not necessarily completely, and which could be safely tolerated, was considered as the maintenance dose.

(c) Maintenance Dosage.—Maintenance doses ordinarly ranged from 45 to 65 mg. in severe cases, 40 to 50 mg. in moderately severe cases, and 25 to 40 mg. in moderate cases. Once established, maintenance therapy was continued without interruption, the dosage being manipulated from time to time to accommodate shifts in disease activity or to control adverse reactions. Routinely the total daily requirement was taken in four divided doses, with a portion ingested at mealtimes and at bedtime. Dosage adjustments were usually made by small increases or decreases of 5 or 10 mg. at a time; large “booster” doses were rarely needed.

Minor endocrine side-effects, such as slight to moderate facial mooning or hypertrichosis, slight peripheral oedema, or irregular glycosuria, were usually looked upon as acceptable annoyances and not as reasons for stopping treatment.

Adjunctive measures such as regulated rest, avoidance of emotional stress, physiotherapy, and a well-balanced diet, relatively low in salt and with caloric restriction when indicated, were prescribed simultaneously. Salicylates were used regularly or irregularly by some patients and intra-articular injections of hydrocortisone acetate were occasionally employed in others to suppress exacerbations in one or two joints.

General Results

Statistical data were analysed in the hope of finding answers to a few general but pertinent questions:

(1) What percentage of patients who were started on hydrocortisone therapy discontinued the hormone and for what reasons? The 150 patients in this study were under observation for periods of 9 to 36 months from the beginning of therapy; more than one-third of them (37 per cent.) were followed for 2 years or longer. Treatment was stopped in 24 patients (16 per cent.), and the remaining 126 (84 per cent.) were still taking the steroid at the time of analysis. Reasons for discontinuances were as follows:

<table>
<thead>
<tr>
<th>Reason for Discontinuation</th>
<th>No.</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insufficient clinical response to warrant further administration</td>
<td>126</td>
<td>84</td>
</tr>
<tr>
<td>Major complications attributable to the hormone</td>
<td>24</td>
<td>16</td>
</tr>
<tr>
<td>Complication unrelated to hydrocortisone</td>
<td>4</td>
<td>2.7</td>
</tr>
<tr>
<td>Death from extraneous causes</td>
<td>1</td>
<td>0.7</td>
</tr>
<tr>
<td>Complete or nearly complete remission in twelve (8 per cent.) patients</td>
<td>3</td>
<td>2</td>
</tr>
</tbody>
</table>

(2) What overall results may be achieved from prolonged hydrocortisone therapy? At the time of analysis, improvement was considered to be adequate or satisfactory in 59 per cent. of patients and
less than satisfactory in 41 per cent. Inadequate degrees of improvement were noted in 62 patients for one or more reasons:

37 (62 per cent.) failed to respond satisfactorily to reasonable sized doses from the beginning of treatment.

Thirteen (22 per cent.) were controlled well at first, but later improvement deteriorated and responsiveness to the hormone diminished.

37 (62 per cent.) developed hormonal side-reactions which prohibited the use of optimally effective doses.

Five (8 per cent.) presented miscellaneous other reasons for limited improvement.

Female patients fared almost as well as male patients: inadequate improvement was recorded in 42 per cent. of the former and in 39 per cent. of the latter.

(3) What are the chief factors which influence the success of therapy? Apart from recognized correctible mistakes in management (i.e. poor selection of patients, inadequate supervision, improper dosage regulation, neglect of appropriate rest, and simple complemental measures such as avoidance of trauma, etc.), which may lead to failure, it was apparent from this study that therapeutic results bore important relationship to two factors—the severity or activity of the disease and the duration of arthritis before treatment.

At the time of analysis improvement was graded as adequate in 36 per cent. of patients with severe, 57 per cent. of patients with moderately severe, and 88 per cent. of patients with moderate disease (Fig. 1). In general, the same problem pertained as with cortisone: for satisfactory control the more severe cases all too often required excessive doses which could not be tolerated or which were considered unsafe for long-term administration. Surely, statistical results would have been more favourable had the series contained a larger percentage of moderate and some mild cases. As might be expected, the remission rate was greater in patients with moderate disease (14·5 per cent.) than in those whose arthritis was moderately severe (7·1 per cent.) or severe (0·025 per cent.).

Percentagewise, results were most favourable when the arthritis was of relatively recent origin. Interestingly, the crucial point was about 2 years, and thereafter as the duration of disease lengthened, the proportion of adequate responses lessened progressively (Fig. 2). Not surprising was the finding that the remission rate was decidedly lower in patients whose disease had been established more than 2 years (4 per cent.) than when the duration was 2 years or less (22 per cent.).

(4) What deterioration of improvement may be expected as treatment is prolonged? Analyses made at intervals during the

---

**Fig. 1.**—Improvement on adequate and inadequate dosage in relation to severity of disease.

**Fig. 2.**—Improvement on adequate and inadequate dosage in relation to duration of disease before starting treatment (years).
The period of observation revealed, as anticipated, that as treatment was continued over the months, the number of patients showing adequate improvement became smaller. The figures (Fig. 3) may be confusing unless it is understood that patients were added to the series as the study progressed and that others were dropped from time to time because of remission, insufficient benefit, or other reasons. The disease was satisfactorily restrained in 72 per cent. of patients at the end of 6 months, but this percentage declined to 59 per cent. at 18 months. At 24 months and later the number demonstrating satisfactory control rose to around 70 per cent.; this is explained by the fact that the majority of patients who became unresponsive or developed unacceptable complications discontinued the hormone within a 2-year period.

(5) What influence does long-term hydrocortisone therapy have on the progress of the disease? Among the 150 patients, fifty (33 per cent.) showed evidence of disease progression during the observation period. Functional capacity was altered significantly by advancement of the arthritis in 31 patients but not in the nineteen others. The ability of steroid therapy to restrain disease progress varied indirectly with the severity or activity of the rheumatoid arthritis. Clinical evidences of progression were noted in 44 per cent. of severe cases, 34 per cent. of moderately severe cases, and 22 per cent. of moderate cases (Fig. 4). An unexpected finding in patients of this series was a lack of correlation between the frequency of disease progression and the duration of the arthritis before therapy (Fig. 5).

It is impossible to judge with full assurance what influence hydrocortisone therapy may have exerted on the natural course of the disease. There are no statistical data available with which to compare the incidence or rate of disease progression in

![Image](http://ard.bmj.com/)

Fig. 3.—Improvement on adequate and inadequate dosage in relation to duration of therapy (months).

![Image](http://ard.bmj.com/)

Fig. 4.—Disease progression in relation to severity of disease.

![Image](http://ard.bmj.com/)

Fig. 5.—Disease progression in relation to duration of disease before starting treatment (years).
untreated or conservatively treated patients in a series of similar composition. Furthermore, the periods of observation in the present study were relatively short (9 to 36 months) in respect to the average span of the disease. However, when consideration is given to the facts that the majority of patients (73 per cent.) suffered from severe or moderately severe forms of rheumatoid arthritis and that they had already failed to respond satisfactorily to conservative management, the incidence of disease progression seems smaller than might have been expected for a similar untreated series. The impression was gained that in cases amenable to hydrocortisone, advancement of the rheumatoid process may frequently be retarded during the period of steroid administration, and perhaps more frequently than heretofore considered.

(6) How satisfactory is hydrocortisone as a long-term treatment agent for rheumatoid arthritis? Orally administered, hydrocortisone must be regarded as a very valuable agent in the management of selected cases of rheumatoid arthritis. It promotes a high rate of immediate therapeutic response and, with relatively low maintenance doses, it is capable of providing continuous, adequate control of the rheumatic manifestations in a significant percentage of cases. Nearly 60 per cent. of patients in the present series, whose arthritis was unsatisfactorily regulated by measures other than steroid therapy, were held in major improvement by the drug during observation periods ranging from 9 to 36 months. Though benefits were less than desired, varying amounts of helpful relief and enhanced functional capacity were furnished to many patients in the remaining 40 per cent.

Nevertheless, hydrocortisone is far from an ideal therapeutic agent for rheumatoid arthritis. Apart from its main deficiency, that of having suppressive rather than curative action, it has, like cortisone, many serious shortcomings. Among these may be listed:

1. The intervention of hormonal side-effects which serve to limit dosage and often satisfactory management, especially in patients with more severe or long-established disease whose daily requirements for the drug are large;
2. The tendency to aggravate certain co-existing pathological conditions, which contra-indicate its use;
3. The decrease in responsiveness and improvement in some patients after prolonged administration;
4. The frequent failure of the hormone to prevent progression of the disease during treatment.

Thus, until a cure for rheumatoid arthritis is found, there is need for an agent which, on systemic administration, will suppress the disease more successfully over long periods and in a higher proportion of patients. A steroid with wide disparity between its anti-inflammatory power and its tendency to produce unwanted effects would partially fulfil this need. That it may be possible to prepare such compounds is suggested by a number of encouraging new developments, which have shown that modifications in the chemical structures of hydrocortisone and cortisone may attenuate those physiological actions which lead to troublesome complications.

Summary

The results of prolonged oral hydrocortisone therapy (9 to 36 months) in 150 consecutive patients with active peripheral rheumatoid arthritis were analysed. The following pertinent statistical information was derived:

1. At the time of analysis, treatment with the hormone had been discontinued in 24 patients (16 per cent.) for the following reasons: insufficient clinical response in four (2·7 per cent.); major complications in two (1·3 per cent.); complications unrelated to hydrocortisone in one (0·7 per cent.); death from extraneous causes in five (3·3 per cent.).
2. Improvement was considered as adequate in 59 per cent. of patients and less than satisfactory in 41 per cent. at the time of analysis.
3. The chief factors which influenced the success of therapy were the severity or activity of the disease and the duration of arthritis before treatment. At analysis, improvement was graded as adequate in 36 per cent. with severe disease, 57 per cent. with moderately severe disease, and 88 per cent. with moderate disease. Results were more favourable when the arthritis was of relatively recent origin; the crucial duration was about 2 years, and thereafter as duration lengthened the proportion of adequate response lessened.
4. As time went on, fewer patients showed adequate improvement. The disease was restrained satisfactorily in 72 per cent. at 6 months and in 59 per cent. at 18 months.
5. Fifty of the 150 patients (33 per cent.) showed evidence of disease progression during the observation period. Functional capacity was not reduced significantly by advancement of the arthritis in 19 of them, but was altered in the remaining 31 patients.

The following conclusions were drawn:

Although hydrocortisone is a very valuable agent in the management of selected cases of rheumatoid arthritis, it is far from an ideal suppressive agent. Like cortisone, it has many shortcomings, chief among which are the intervention of hormonal side-effects, especially when dosage requirements are large; the tendency to aggravate certain co-existing pathological conditions; the development of unresponsiveness in some patients after prolonged administration; the failure to prevent disease progression in an appreciable percentage of cases.
ORAL HYDROCORTISONE IN RHEUMATOID ARTHRITIS

Thus, until a cure for rheumatoid arthritis is found, there is still need for an agent which will suppress the disease more successfully. That such a compound may be forthcoming is suggested by recent discoveries of steroids related to hydrocortisone and cortisone which possess wider dissociation the anti-inflammatory properties and the other unwanted physiological activities.

REFERENCES

(1953b). Annals of the Rheumatic Diseases, 12, 125.

Blakiston, Philadelphia.

Hydrocortisone por voie bucale dans l'arthrite rhumatismale

RÉSUMÉ

On analysed les résultats du traitement prolongé (9 à 36 mois) à l'hydrocortisone par voie bucale de 150 malades consécutifs atteints d'arthrite rhumatismale périphérique. On obtint des données statistiques pertinentes que voici:

(1) Au temps de l'enquête, le traitement à l'hormone se trouvait interrompu chez 24 malades (16%) pour des raisons suivantes: réponse clinique insuffisante 4 (2,7%); complications majeures 2 (1,3%); complications indépendantes de l'hormone 1 (0,6%); morts de causes différentes 5 (3,3%); remission 12 (8%).

(2) À l'heure de l'enquête, l'amélioration fut considérée satisfaisante chez 59% des malades et moins que satisfaisante chez 41%.

(3) L'issue du traitement dépendait de deux facteurs principaux: la sévérité ou bien l'activité de la maladie et l'âge de l'arthrite avant le traitement. A l'enquête on a classé 36 % des malades graves, 57 % des assez graves et 88 % des modérément atteints parmi les améliorés d'une manière satisfaisante. Les résultats ont été plus favorables dans l'arthrite récemment active, avec une durée de deux ans à peu près, après quoi la proportion des améliorations satisfaisantes diminuait au fur et à mesure que l'ancienneté de l'arthrite augmentait.

(4) Avec le temps, le nombre d'améliorations satisfaisantes diminue de 72% des cas au bout de 6 mois et 59% des cas seulement au bout de 18 mois.

(5) Chez 50 (33%) malades sur 150 au cours de la période sous observation on notait des signes d'évolution de la maladie. Chez 19 d'entre eux l'aggravation de l'arthrite n'a pas entraîné de réduction appréciable de la capacité fonctionnelle, mais elle l'a altéré chez les 31 restants.

On tire des conclusions suivantes:

Bien que l'hydrocortisone soit un moyen très utile dans le traitement des cas déterminés d'arthrite rhumatismale, elle est loin d'être un agent idéal de suppression. Comme la cortisonne, elle a ses défauts dont le principal est le pouvoir de provoquer des réactions endocriniennes secondaires; surtout lorsqu'on doit administrer des doses élevées; elle tend à aggraver certains états mornes coexistants; certains malades cessant à répondre à son administration prolongée et dans un nombre appréciable de cas elle n'arrive pas à arrêter l'évolution de la maladie.

Il s'en suit, qu'à moins qu'on trouve une cure, on aura toujours besoin d'un moyen plus satisfaisant pour juger l'arthrite rhumatismale. La découverte récente des stéroïdes apparentés à l'hydrocortisone et à la cortisonne, dans lesquels le pouvoir anti-inflammatoire et certaines propriétés physiologiques indésirables se trouvent plus dissociés, semble indiquer qu'un tel moyen ne se fera pas attendre.

Hidrocortisona por via oral en la artritis reumatoide

SUMARIO

Se analizaron los resultados de tratamiento prolongado (9 a 36 meses) con hidrocortisona por via oral de 150 enfermos consecutivos con artritis reumatoide periférica. Los siguientes datos estadísticos pertinentes fueron obtenidos:

(1) Al tiempo del análisis, en 24 enfermos (16%) se dejó el tratamiento hormonal por razones siguientes: respuesta clínica inadecuada, 4 (2.7%); complicaciones mayores, 2 (1.3%); complicaciones independientes de la hidrocortisona, uno (0.7%); muertos de causas ajenas, 5 (3.3%); remisión, 12 (8%).

(2) Al tiempo del análisis, la mejora se juzgó satisfactoria en el 59% de los enfermos y poco satisfactoria en los demás 41%.

El éxito del tratamiento dependió de dos factores principales: la severidad o la actividad de la enfermedad y la duración de la artritis antes del tratamiento. En el análisis el 36% de los enfermos graves, el 57% de los bastante graves y el 88% de los moderados fueron clasificados como satisfactoriamente mejorados. Los resultados fueron mejores en la artritis relativamente reciente, con duración crítica de dos años aproximadamente; luego, la proporción de las mejoras satisfactorias bajaba a medida que la antigüedad de la artritis aumentaba.

(4) El número de las mejoras satisfactorias disminuía con el tiempo. La enfermedad estaba contenida en un 72% de los casos a cabo de seis meses y en un 59% solamente después de dieciocho meses.

(5) Durante el periodo de observación se notaron signos de evolución en 50 de los 150 enfermos. En 19 de ellos la agravación de la artritis no fué seguida de reducción apreciable de la capacidad funcional, alterada en los demás 31.

Se llegó a las conclusiones siguientes:

Aunque la hidrocortisona sea un medio muy útil en el tratamiento de casos determinados de artritis reumatoide, le falta mucho para ser un agente represivo ideal. Como la cortisona, tiene sus defectos entre los cuales se destaca su propensión de causar reacciones hormonales secundarias, en particular cuando se necesitan dosis elevadas; su tendencia a agravar ciertas afecciones coexistentes; algunas enfermedades dejan de responder a su administración prolongada y, en un número apreciable de casos, no llega a contener la evolución morbida.

Así pues, a menos de hallar una cura, un medio más satisfactorio para contener la artritis reumatoide aún nos hace falta. La reciente descubierta de esteroides relacionados con la hidrocortisona y la cortisona, en los cuales el poder anti-inflamatorio y ciertas propiedades fisiológicas indeseables están disociadas parece indicar que la descubierta de un tal medio no está lejos.

Downloaded from http://ard.bmj.com/ on October 13, 2017 - Published by group.bmj.com
Oral Hydrocortisone Therapy in Rheumatoid Arthritis: An Appraisal of General Results of Prolonged Administration

Edward W. Boland

doi: 10.1136/ard.14.3.232

Updated information and services can be found at:

http://ard.bmj.com/content/14/3/232.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/